• レポートコード:MRC2303M001 • 出版社/出版日:Mordor Intelligence / 2023年1月23日 • レポート形態:英文、PDF、127ページ • 納品方法:Eメール(受注後2-3営業日) • 産業分類:医薬品 |
Single User | ¥712,500 (USD4,750) | ▷ お問い合わせ |
Corporate License | ¥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の本調査資料によると、世界の局所麻酔薬市場規模が、2021年に2,658.64百万ドルとなり、2027年まで年平均成長率4.68%で拡大し、3,534.4百万ドルに達すると予測されています。本書は、局所麻酔薬の世界市場にフォーカスし、最新動向と今後の市場性などをまとめており、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤別(ブピバカイン、リドカイン、ベンゾカイン、ロピバカイン、その他)分析、投与別(注射薬、表面麻酔薬)分析、地域別(アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン)分析、競争状況、市場機会・将来の動向などが掲載されています。また、Baxter International Inc.、Fresenius SE & Co. KGaA、Glenmark Pharmaceutical Inc.、Mylan NV、Pacira Pharmaceuticals Inc.、Pfizer Inc.、Septodont、Teva Pharmaceutical Industries Ltd、Aspen Pharmacare、Nuventra Pharma Sciences、Endo Pharmaceuticals、Actavisなど、主要企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の局所麻酔薬市場規模:薬剤別 - ブピバカインの市場規模 - リドカインの市場規模 - ベンゾカインの市場規模 - ロピバカインの市場規模 - その他の市場規模 ・世界の局所麻酔薬市場規模:投与別 - 注射薬における市場規模 - 表面麻酔薬における市場規模 ・世界の局所麻酔薬市場規模:地域別 - 北米の局所麻酔薬市場規模 アメリカの局所麻酔薬市場規模 カナダの局所麻酔薬市場規模 メキシコの局所麻酔薬市場規模 … - ヨーロッパの局所麻酔薬市場規模 イギリスの局所麻酔薬市場規模 フランスの局所麻酔薬市場規模 イタリアの局所麻酔薬市場規模 … - アジア太平洋の局所麻酔薬市場規模 中国の局所麻酔薬市場規模 インドの局所麻酔薬市場規模 日本の局所麻酔薬市場規模 … - 南米/中東の局所麻酔薬市場規模 ブラジルの局所麻酔薬市場規模 アルゼンチンの局所麻酔薬市場規模 南アフリカの局所麻酔薬市場規模 … - その他地域の局所麻酔薬市場規模 ・競争状況 ・市場機会・将来の動向 |
The global local anesthesia drugs market was valued at USD 2,658.64 million in 2021, and it is expected to reach USD 3,534.41 million by 2027, registering a CAGR of 4.68% during the forecast period.
The use of local anesthesia in treating patients infected with COVID-19 is in high demand due to its benefits and minimal risk of viral transmission. Additionally, as per an article published in October 2020, titled “Topical Lignocaine Anesthesia for Oropharyngeal Sampling for COVID-19,” topical oropharyngeal lignocaine applications significantly increased comfort levels for the patient during oropharyngeal sampling for COVID-19 and did not affect the detection of SARS-CoV-2 in the upper airway. Thus, the study suggested that topical oropharyngeal lignocaine should be considered as a measure to reduce the viral inoculum sampling of a person suspected of being infected by COVID-19. Such studies are likely to boost the administration and use of local anesthesia drugs in treating COVID-19 patients globally.
Further, the growth of the local anesthesia drugs market is driven by various factors such as the rising number of surgeries, new approval of anesthetic drugs, and the growing use of local anesthetics in post-operative pain. The increasing number of surgeries was a major factor driving the market growth over the study period. For instance, as per the Plastic Surgery Statistics Report by the American Society of Plastic Surgeons, in 2020, the total number of cosmetic procedures performed were 2,314,720, including 211,067 procedures of liposuction in the US. As local anesthesia is widely used in such procedures, the growth in the number of such surgeries performed will propel the demand for anesthesia drugs. Furthermore, the development and approvals of novel local anesthesia drugs are proving to be a new revenue-generating resource for market players. For instance, in February 2021, PainPass launched the first Cannabidiol (CBD)/lidocaine product line targeting those with chronic pain and for numbing muscles externally.
However, the side effects of these drugs and strict regulatory framework are expected to restrain the market studied.
Local Anesthesia Drugs Market Trends
Bupivacaine Expected to Register Significant Growth over the Forecast Period
By drug type, bipuvicane is expected to witness significant growth over the forecast period. Bupivacaine is a prescription medication used as a local anesthetic to block the nerve impulses that send pain signals to the brain. This injection is used as an anesthetic for local and regional anesthesia for several procedures, such as surgery and diagnostic, therapeutic, and obstetrical procedures. Thus, the growing number of surgeries globally will fuel the demand for bipuvicane in the near future.
Furthermore, several market players are engaged in implementing strategic initiatives, thereby contributing to market growth. For instance, in March 2021, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) submitted by Pacira BioSciences Inc. for the expanded use of its Exparel (Bupivacaine Liposome Injectable Suspension) in pediatric patients. Hence, the increasing number of surgeries and product developments is augmenting the demand for bipuvicane, and it is expected to propel the segment’s growth over the forecast period.
North America Dominates the Market and Expected to Continue Dominance over the Forecast Period
Within North America, the US holds the major share of the market. This can be attributed to the increasing number of surgeries, the rising aging population suffering from chronic conditions, the growing use of local anesthetics in post-operative pain, and advancements in anesthesia administration. For instance, according to the American Society of Plastic Surgeons (ASPS), in 2020, about 768,000 total cosmetic procedures were performed in people aged 10-29 years, and 6.1 million total cosmetic procedures were performed among the age group of 40-54-year-olds. These statistics indicate that surgical procedures are constantly increasing in the region, ultimately driving the demand for anesthesia drugs.
Moreover, several market players are also engaged in implementing strategic initiatives, which are contributing to market growth. For instance, in December 2021, Hikma Pharmaceuticals PLC (Hikma) launched Bupivacaine HCl Injection USP through its US affiliate Hikma Pharmaceuticals USA Inc. The company launched 0.25%, 0.5%, and 0.75% in 10 milliliter and 30 milliliter doses.
Such developments coupled with growth in the number of surgeries using anesthesia drugs are anticipated to bolster market growth in the region.
Local Anesthesia Drugs Market Competitor Analysis
The local anesthesia drugs market is competitive with several global players operating in the market. Companies are focusing on major collaborations, mergers, and acquisitions in order to enhance their market share. The major market players are Fresenius SE & Co. KGaA, Septodont, Pfizer Inc., Baxter International Inc., and Pacira Pharmaceuticals Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definiton
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Surgeries
4.2.2 New Approval of Anesthetic Drugs
4.2.3 Growing Use of Local Anesthetic for Post-operative Pain
4.3 Market Restraints
4.3.1 Side Effects of Anesthetic Drugs
4.3.2 Regulatory Framework
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size By Value – USD Million)
5.1 By Drug Type
5.1.1 Bupivacaine
5.1.2 Lidocaine
5.1.3 Benzocaine
5.1.4 Ropivacaine
5.1.5 Prilocaine
5.1.6 Chloroprocaine
5.1.7 Other Drug Types
5.2 By Mode of Administration
5.2.1 Injectable
5.2.2 Surface Anesthetic
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Fresenius SE & Co. KGaA
6.1.3 Glenmark Pharmaceutical Inc.
6.1.4 Mylan NV
6.1.5 Pacira Pharmaceuticals Inc.
6.1.6 Pfizer Inc.
6.1.7 Septodont
6.1.8 Teva Pharmaceutical Industries Ltd
6.1.9 Aspen Pharmacare
6.1.10 Nuventra Pharma Sciences
6.1.11 Endo Pharmaceuticals
6.1.12 Actavis
7 MARKET OPPORTUNITIES AND FUTURE TRENDS